Biopharma Daily Stock Updates - 04/23/21

$XBI $134.30 -0.2%

Covid Updates

$INO -25% US govt will not fund Ph3 due to increased EUA vaccines in the U.S. Ph3 trial to be ex-US. source


$VRNA -3.8% Pilot study results reported for Ensifentrine trial in COVID-19 hospitalized patients. source


Pipeline Updates

$ADCT -4.6% ZYNLONTA approved by FDA to treat r/r DLBCL. source


$ARNA +0.2% Etrasimod patient reported outcomes data from Phase 2b trial presented. source


$CHRS +1.8% Toripalimab achieves primary endpoints of progression free survival and overall survival. source


$TARA -18.4% Received FDA feedback for TARA-002 trial; plan to initiate pediatric trial in H2 2021. source


$NVAX +0.2% Matrix-M Phase 2b trial results published in The Lancet and initiated Phase 3 trial. source


$CALT +5.0% Nefecon granted accelerated assessment procedure by CHMP. source


$GLPG -1.2% Submitted NDA in Japan for approval of filgotinib to add UC indication to label. source


$ANAB +3.5% FDA approves JEMPERLI for DMMR endometrial cancer. source


$RMTI +13.9% Present data on Iron Deficiency Anemia Management at NHIA 2021 conference. source


Finance Updates

$JAGX +12.5% Webcast interview of company's founder, president, and CEO. source


$OCGN +3.7% Entered into agreements with investors for sale of 10 million shares of common stock. source

0 comments